TipRanks
2 .有强劲买入力的低价股，可以产生巨大的利润
好吧，这是官方的。Joe Biden现在是总统，并得到支持 - 至少在短期内，由国会两个大会的民主多数。华尔街正在采取新政府的行动，并在财政刺激的第一步飙升，预计将提高消费者支出，权衡公司盈利，并在2021年上半年提供一般经济支持，高盛的情况投资策略师大卫·克斯坦对财政刺激措施的近期观乐观态度。在此背景下，Kostin将今年的GOLDMAN展望达到6.4％的GDP增长。他认为明年持续高增长，并将预测设定为4％。这些前景数据高于先前发布的5.9％和3.7％。为此，克朗琅在今年年底之前认为标准普尔500指数达到4,300人，这是目前水平的12％。“选举有后果。华盛顿民主控制，直流1月20日之后将带来更高的预算支出，更快的GDP增长，比我们预期的更高的GDP增长，更高的利率，“克朗丁指出。 As the markets look up, investors look for stocks that are ready for profit. Penny stocks, stocks priced less than $ 5 per share, are a natural place to look for potential winners. Their low price means that even a small increment will result in large percentages. Before investing directly in any penny stock investment, however, Wall Street pros recommend looking at the bigger picture and considering other factors beyond price. Some names that fall into this category really get what you pay for with little long-term growth prospects due to weak fundamentals, recent headwinds, or even large stocks outstanding. With the risk in mind, we used TipRanks’ database to find compelling penny stocks with cheap price tags. The platform led us to two tickers with stock prices below $ 5 and analyst consensus ratings with “strong buy”. Not to mention significant upside potential. AzurRx BioPharma (AZRX) We’re starting a company specializing in gastrointestinal diseases, AzurRx. This company focuses on the development of non-systemic, targeted recombinant therapies for GI diseases. AzurRx has a pipeline of three drug candidates at multiple levels of the development process. The key candidate for the pipeline, MS1819, is currently being investigated for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is a recombinant lipase derived from a strain of yeast. The drug targets fat molecules in the digestive tract and allows patients to absorb the broken down fats for nutritional value. The drug is currently in phase 2 trials, which are expected to be completed in the first half of this year. As of January 21, the first two patients in the Phase 2b OPTION 2 extension study were given treatment and the Data Monitoring Committee (DMC) “continues to support the program.” In another major development, AzurRx announced earlier this month that it is partnering with First Wave Bio to develop the oral and rectal formulations of niclosamide for the treatment of Immune Checkpoint Inhibitor Associated Colitis (ICI-AC) and COVID-19 -to study gastrointestinal infections caused by the disease. The estimated market for niclosamide for treating COVID-related GI problems exceeds $ 450 million. Based on several potentially significant clinical catalysts plus the $ 0.98 share price, several members of the street believe now is the right time to pull the trigger. Roth Capital’s Jonathan Aschoff is bullish on AzurRx and bases his longer-term projections on the likely success of MS1819. “We base our assessment for AZRX on projected future US sales of MS1819 for the treatment of EPI due to CF and CP. It uses an initial annual price of approximately $ 18,000, a price that is consistent with currently available PERTs. We estimate MS1819 will be commercialized in the US in 2023 and will have sales of $ 272 million in 2030. The commercial success of MS1819 outside the US or the commercial success of the early stage beta-lactamase program would have a positive impact on our assessment, ”said Aschoff. The analyst is also looking forward to the first clinical results of niclosamide in COVID-19 GI infections and ICI-AC, noting: “Niclosamide was approved by the FDA in 1982 for the treatment of tapeworm infections in the intestine and is on the list of major drugs With all of these factors in mind, Aschoff rates AZRX as a buy, and its target price of $ 7 points to a sky-high positive, given the millions of patients who have taken the drug, the safety profile has been largely determined, reducing the risk of development up 608% for the year ahead. (To see Aschoff’s track record, click here) Overall, analyst consensus on AZRX stock is a strong buy; the stock has 4 recent valuations including 3 buys and a single hold. Additionally, the average target price of $ 4 brings the upside potential to 304%. (See AZRX stock analysis on TipRank s) ProQR (PRQR) ProQR is a biotechnology company focused on treatments for congenital progressive blindness. In particular, the company is working on drugs to reverse a group of genetic visual disorders called hereditary retinal diseases. These diseases currently have no effective treatments. The company has a research pipeline of five drug candidates. The two most distant are QR-110 (Sepofarse) and QR-421. Of these two, QR-110 is currently in phase 2/3 studies. This candidate is RNA therapy to correct the m The most common CEP290 gene mutation that causes congenital liver amaurosis 10 (LCA10). This is a serious genetic retinal disease that affects up to 3 in 100,000 children. QR-421 is another RNA therapy that focuses on exon 13 mutations in the USH2A gene. These mutations cause blindness due to retinitis pigmentosa and / or Usher syndrome. QR-421 is in Phase 1/2 studies with the aim of restoring lost vision or preventing it from happening at all. Analyst Jonathan Wolleben covers the stock for JMP, pointing to Sepo arsenic as a key component of his bullish thesis. “We still see the chance of success of sepo arsenic at Illuminate as good for several reasons: 1) Phase 1/2 confirmed the intended registration dose and the dosing interval (6 months); 2) patients had clinically significant and sustained BCVA improvements after 12 months – key primary endpoint; 3) supporting secondary effectiveness measures (FST, mobility); 4) similar reactions in second treated eyes; 5) long-term safety confirms positive risk / benefit; and 6) The illuminated patient population was enriched based on the Phase 1/2 results (baseline vision of> / = hand movement). We assign sepofarsen a POS of 60% and the model LCA10 as an opportunity of ~ 300 million USD for PRQR with maximum penetration, “said Wolleben. In line with his optimistic outlook, Wolleben sets a price target of 20 USD for the share, what a Year of 384% implies up, along with an Outperform (i.e. Buy) rating. (To see Wolleben’s track record, click here.) Overall, PRQR receives a unanimous Strong Buy rating from analyst consensus based on 3 positive stock valuations currently trading $ 4.13, and the average target price of $ 20.67 is slightly more bullish than Wolleben’s, indicating an upward move of 400% for the next 12 months. (See PRQR stock analysis at TipRanks) To get good ideas for To find penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks Conclusion: The opinions expressed in this article are solely those of the analysts presented. The content is intended to be used for informational purposes only. He is very impo You must do your own analysis before making any investment.
评论都关门了。